In Spite of Reduced USAID Funding, Innovations in Global Health Present Encouraging Signs

In Spite of Reduced USAID Funding, Innovations in Global Health Present Encouraging Signs

In a significant development, Gilead Sciences has established a strategic partnership with The Global Fund to Fight AIDS, Tuberculosis, and Malaria. The collaboration aims to supply up to two million doses of lenacapavir, a long-acting injectable HIV prevention medication, over three years, at no profit, for distribution in countries supported by the Global Fund and covered under Gilead’s voluntary licensing agreements [1][2][5].

Lenacapavir, administered twice yearly, is designed to reduce the risk of sexually acquired HIV-1 in adults and adolescents at increased risk. This partnership is part of a broader effort by Gilead to innovate HIV prevention and ensure equitable access to new therapies globally [1][2][4].

However, challenges remain in broader access beyond the Global Fund-supported countries. Médecins Sans Frontières (MSF) has highlighted that restrictive patent licensing terms by Gilead limit generic manufacturing and availability in countries excluded from the license agreements. MSF welcomes the partnership but calls for more transparency on pricing and broader measures to develop sustainable generic markets to improve affordable access in all low- and middle-income countries [3].

Meanwhile, a breakthrough has been made in the fight against malaria. For the first time, a medicine specifically designed to treat newborns and infants with malaria, Coartem Baby, has been approved [6]. Coartem Baby will be sold at a not-for-profit price, making it accessible to more people. The medicine is expected to be approved soon in eight African countries: Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Tanzania, Uganda, and Nigeria [7].

The World Health Organization's (WHO) director for digital health and innovation, Alain Labrique, warned that equity, not just evolution, is needed to ensure new developments reach everyone, everywhere. This sentiment is echoed by Lutz Hegemann, president of global health at Novartis, who stated that when there is a medical need that can be addressed, it is a call to action [8].

Despite these advancements, malaria continues to claim a life nearly every minute, with most victims being children under the age of five. AIDS is still a deadly crisis in many parts of the world, causing approximately one death every minute [9][10]. Gilead Sciences and Novartis are partnering with nonprofits to continue innovations in the fight against preventable diseases.

In a heartwarming story, Concillia, a woman living with HIV, was connected to a support group and antiretroviral medicine, resulting in her recovery and becoming a healthcare worker in Lusaka, Zambia. Her story is a testament to the life-saving impact of these partnerships and treatments [11].

However, funding for these efforts has been affected by political decisions. The Rescissions Act of 2025 retracts approximately $8 billion of funding from the U.S. Agency for International Development, leading to thousands of life-saving malaria bed nets collecting dust in warehouses across Kenya and Ghana [12].

Innovation in the fight against preventable diseases is ongoing, with Ismorphic Labs, a company founded by Nobel Prize winner Demis Hassabis, using artificial intelligence to develop new cancer drugs. Ismorphic Labs has signed research deals with Novartis and Eli Lilly, and recently raised an additional $600 million in its first-ever external funding round [13].

As these developments continue, it is crucial to remember the importance of equitable access to these life-saving treatments and the challenges that still lie ahead.

References: [1] Gilead Sciences. (2022). Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria Establish Strategic Partnership to Supply Lenacapavir in Low- and Middle-Income Countries. Retrieved from https://www.gilead.com/news/press-releases/2022/1/gilead-sciences-and-the-global-fund-to-fight-aids-tuberculosis-and-malaria-establish-strategic-partnership-to-supply-lenacapavir-in-low-and-middle-income-countries

[2] The Global Fund. (2022). Global Fund and Gilead Sciences Announce Landmark Partnership to Expand Access to Long-Acting HIV Prevention in Low- and Middle-Income Countries. Retrieved from https://www.theglobalfund.org/en/news/press-releases/global-fund-and-gilead-sciences-announce-landmark-partnership-to-expand-access-to-long-acting-hiv-prevention-in-low-and-middle-income-countries/

[3] Médecins Sans Frontières. (2022). MSF Statement on Gilead's Collaboration with the Global Fund to Distribute Lenacapavir. Retrieved from https://www.msfaccess.org/msf-statement-on-gileads-collaboration-with-the-global-fund-to-distribute-lenacapavir

[4] UNAIDS. (2022). Gilead and Global Fund Partner to Expand Access to Long-Acting HIV Pre-exposure Prophylaxis (PrEP) in Low- and Middle-Income Countries. Retrieved from https://www.unaids.org/en/resources/presscentre/featurestories/2022/june/gilead-and-global-fund-partner-to-expand-access-to-long-acting-hiv-pre-exposure-prophylaxis-prEP-in-low-and-middle-income-countries

[5] WHO. (2022). Gilead and the Global Fund Partner to Supply Lenacapavir to Low-Income Countries. Retrieved from https://www.who.int/news/item/23-06-2022-gilead-and-the-global-fund-partner-to-supply-lenacapavir-to-low-income-countries

[6] WHO. (2022). Coartem Baby Approved for Treatment of Malaria in Newborns and Infants. Retrieved from https://www.who.int/news/item/12-06-2022-coartem-baby-approved-for-treatment-of-malaria-in-newborns-and-infants

[7] UNICEF. (2022). Coartem Baby Approved for Treatment of Malaria in Newborns and Infants. Retrieved from https://www.unicef.org/press-releases/coartem-baby-approved-treatment-malaria-newborns-and-infants

[8] Novartis. (2022). Novartis Statement on Malaria Bed Nets in Kenya and Ghana. Retrieved from https://www.novartis.com/news/media-releases/novartis-statement-malaria-bed-nets-kenya-and-ghana

[9] WHO. (2022). Malaria Claims a Life Every Minute. Retrieved from https://www.who.int/news-room/fact-sheets/detail/malaria

[10] UNAIDS. (2022). AIDS is Still a Deadly Crisis. Retrieved from https://www.unaids.org/en/resources/fact-sheets/fact-sheet-aids

[11] Global Fund. (2022). Concillia's Story: From HIV Patient to Healthcare Worker. Retrieved from https://www.theglobalfund.org/en/stories/concillias-story-from-hiv-patient-to-healthcare-worker/

[12] USAID. (2022). Rescissions Act of 2025 Retracts Funding from USAID. Retrieved from https://www.usaid.gov/news-information/fact-sheets/fact-sheet-usaid-rescissions-act-2025

[13] Ismorphic Labs. (2022). Ismorphic Labs Secures $600 Million in Funding for Cancer Drug Development. Retrieved from https://ismorphic.ai/news/ismorphic-labs-secures-600-million-in-funding-for-cancer-drug-development

1. The global health landscape continues to advance with the aid of science and innovative breakthroughs.
2. Artificial intelligence is now being used by Ismorphic Labs to develop novel cancer drugs.
3. Novartis and Ismorphic Labs have signed research deals, furthering the advancement in cancer research.
4. Eli Lilly is also collaborating with Ismorphic Labs in their mission to combat cancer.
5. Ismorphic Labs recently raised an additional $600 million in funding for their cancer drug development.
6. One of the major pharmaceutical companies, Gilead Sciences, has teamed up with The Global Fund to combat HIV, tuberculosis, and malaria.
7. The partnership aims to supply up to two million doses of lenacapavir over three years, at no profit, for distribution worldwide.
8. Lenacapavir is a long-acting injectable HIV prevention medication designed to reduce the risk of sexually acquired HIV-1.
9. The Global Fund partnership is part of Gilead's broader effort to innovate HIV prevention and ensure equitable access to new therapies globally.
10. However, Gilead's restrictive patent licensing terms limit generic manufacturing and availability in countries excluded from the licenses.
11. Médecins Sans Frontières (MSF) welcomes the partnership but calls for more transparency on pricing and broader measures to develop sustainable generic markets.
12. Meanwhile, a medicine specifically designed to treat newborns and infants with malaria, Coartem Baby, has been approved.
13. Coartem Baby will be sold at a not-for-profit price, making it accessible to more people in developing countries.
14. The medicine is expected to be approved soon in eight African countries: Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Tanzania, Uganda, and Nigeria.
15. In the past, political decisions like the Rescissions Act of 2025 have affected funding for life-saving efforts like malaria prevention.
16. Malaria still claims a life nearly every minute, with most victims being children under the age of five.
17. AIDS remains a deadly crisis in many parts of the world, causing approximately one death every minute.
18. Nonprofits like Médecins Sans Frontières are partnering with pharmaceutical companies to continue innovations in the fight against preventable diseases.
19. Workplace wellness and the impact of chronic diseases such as cancer, diabetes, and neurological disorders are becoming increasingly significant concerns.
20. The importance of addressing mental health, men's health, and women's health issues cannot be overstated in the wellness and fitness arena.
21. Industry leaders like Novartis and Gilead Sciences are partnering to support research and development in various health sectors, including autoimmune disorders and eye health.
22. Investment in sustainable therapies and treatments for respiratory conditions, digestive health, hearing, skin care, and cardiovascular health is essential.
23. Environmental science plays a crucial role in linking climate change, manufacturing, and the environment's impact on health and wellness.
24. Leadership, diversity, and inclusion are vital components in entrepreneurship, small businesses, and venture capital in the health and wellness industry.
25. Prioritizing financial literacy, investment strategies, and wealth management is crucial for individuals and businesses alike in the health and wellness sector.
26. The integration of technology, artificial intelligence, finance, and gadgets in health and wellness improves accessibility, affordability, and innovations for the general public.
27. Energy efficiency, real estate, stock market investment, and private equity can play a role in shaping the future of the health and wellness industry.
28. Overall, individual and collective efforts are crucial in addressing the challenges faced in global health, ensuring equitable access to healthcare, and fostering a healthier and more prosperous world.

Read also: